Pancreatic Adenocarcinoma Therapeutics Market Size Analysis To 2019

Pancreatic Adenocarcinoma Therapeutics Market Size, Share, Trends,
Company Profiles, Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast To 2019
Pancreatic adenocarcinoma is also referred to as pancreatic cancer (PC). It is an illness primarily
affecting the elderly populace. Seventy five percent of pancreatic adenocarcinomas are detected
in patients aged more than seventy five years. Pancreatic cancer grows fast, is asymptomatic
initially, and displays only non-specific symptoms later.
Premature diagnostic PC procedures do not exist. At present, the best alternative for patients to
survive is resection. Resistance disease is eventually seen in most of the patients. These patients
are historically restricted from availing therapeutic alternatives. Their treatment involves
fluorouracil for combination treatments or as monotherapy.
Gemcitabine refractory disease recently led to sanctioning ‘Onivyde’ in 2015. This has boosted
the survival chances of resistant patients. But diversification of therapeutic alternatives for these
patients faces demand from clinics. Existing drugs for late PC stages cater to this demand,
however treatments till now have not yielded promising results. None of the treatments has
shown positive results.
Read Complete Report with TOC: http://www.radiantinsights.com/research/pancreaticadenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipelineshows-diversity-of-novel-targets-though-commercial-impact-remains-distant
Due to this, PC cases owing to expanding worldwide population and obesity & diabetes
prevalence are predicted to be significant propellers of pancreatic adenocarcinoma therapeutics
in major developed markets (during the forecast period). Currently, the market stands around
USD 1.9 billion and should attain about USD 2.9 billion (in terms of incomes) by 2021.
PA has weak prognosis, making drug developments difficult, deeming wise benefit/price ratios
and cautious investors. Weak sales opportunities with PA treatment developments could
discourage prospective investors. In spite of some enhancements in failures, more mutation
explanations & their effects on disease progression are needed.
This need can arise prior to the attainment of less failures and development of effective
combination treatments. One of the recent studies states that these developed markets are led by
gemcitabine, a widely used generic for its efficiency & affordability. Even if pipeline drugs cost
the same as gemcitabine, their weak efficiency rates compared to current therapeutics don’t
provide robust price to benefit ratios.
For this reason, majority of the drugs projected to receive sanction (in the future) could be used
for combination treatments. This may deter adenocarcinoma therapeutics in major developed
markets to reduce their shares and charge high prices.

Table Of Content:
Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Overview 9
2.1.1 Pancreatic Neuroendocrine Tumors 10
2.2 Pathophysiology 11
2.2.1 Inherited Disease 11
2.2.2 Somatic Mutations 11
2.3 Signs and Symptoms 12
2.4 Risk Factors 13
2.4.1 Smoking 13
2.4.2 Pancreatitis and Other Medical Conditions 13
2.4.3 Obesity 13
2.4.4 Infections 13
2.5 Diagnosis 13
2.6 Treatment Algorithm 14
2.6.1 Surgery 14
2.6.2 Radiation Therapy 14
2.6.3 Chemotherapy 15
2.6.4 Algorithm of Chemotherapeutic Treatment for Pancreatic Cancer 16
Browse All Reports of This Category @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
3 Marketed Products 33
3.1 Approved Products 33
3.1.1 Gemcitabine 33
3.1.2 IV Fluorouracil 34
3.1.3 Tarceva 34
3.1.4 Abraxane 35
3.1.5 Teysuno/TS-1 36
3.2 Off-Label Products 36
3.2.1 Xeloda 36
3.2.2 Eloxatin 37
3.3 Marketed Products - Discussion 37
4 Product Pipeline 39
4.1 Pipeline Overview 39
4.2 Overview of Pipeline by Phase, Route of Administration, Molecule Type and Molecular
Target 39
4.3 Key Trends in Drug Development within the Pancreatic Cancer Pipeline 44

4.3.1 Enhancing Drug Delivery 44
4.3.2 Targeted Therapies 44
4.3.3 Immunotherapy 45
4.4 Clinical Trial Duration and Size 47
4.5 Clinical Trial Failure Rate 50
4.6 Clinical Trial Discussion 51
4.7 Promising Drug Candidates in Pipeline 53
4.7.1 Masivet/Kinavet (US) - AB Science 53
4.7.2 Glufosfamide - Eleison Pharmaceuticals Incorporated 54
4.7.3 Tertomotide - Kael-GemVax Co., Ltd 55
4.7.4 TH-302 - Threshold Pharmaceuticals 56
4.7.5 HyperAcute Pancreas - NewLink Genetics Corporation 58
4.7.6 MM-398 - Merrimack Pharmaceuticals Inc. 60
4.8 Pipeline Discussion 62
Request Free Sample Of This Study @
http://www.radiantinsights.com/research/pancreatic-adenocarcinoma-therapeutics-inmajor-developed-markets-to-2019-early-stage-pipeline-shows-diversity-of-novel-targetsthough-commercial-impact-remains-distant#tabs-4
5 Market Forecast 67
5.1 Introduction 67
5.2 Global Market 67
5.3 North America 70
5.3.1 Treatment Usage Patterns 70
5.3.2 Annual Cost of Therapy 71
5.3.3 Market Size 73
5.4 Top Five European Countries 75
5.4.1 Treatment Usage Patterns 75
5.5 Annual Cost of Therapy 77
5.6 Market Size 79
5.7 Japan 81
5.7.1 Treatment Usage Patterns 81
5.7.2 Annual Cost of Therapy 82
5.7.3 Market Size 82
5.8 Drivers and Barriers 83
5.8.1 Drivers 83
5.8.2 Barriers 84
6 Deals 87
6.1 Licensing Deals 87
6.1.1 Clavis Enters Licensing and Development Agreement with Clovis 89
6.1.2 Baxter Enters Licensing Agreement with Onconova for Rigosertib 90
6.1.3 Lorus Therapeutics Enters Into Licensing Agreement with Zor Pharma 90

6.1.4 Novogen Enters Into Licensing Agreement with Marshall Edwards For NV-196 And NV-
143 90
6.2 Co-Development Deals 90
6.2.1 Merck Serono Enters Into Co-Development Agreement with Threshold Pharma for TH-302
92
7 Appendix 93
7.1 All Pipeline Drugs by Phase 93
7.1.1 Discovery 93
7.1.2 Preclinical 95
7.1.3 IND/CTA-Filed 103
7.1.4 Phase I 103
7.1.5 Phase II 105
7.1.6 Phase III 110
Access Full Report: http://www.radiantinsights.com/research/pancreatic-adenocarcinomatherapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-shows-diversity-ofnovel-targets-though-commercial-impact-remains-distant
7.1.7 Pre-Registration 111
7.2 Market Forecasts to 2019 111
7.2.1 Global 111
7.2.2 US 112
7.2.3 Canada 112
7.2.4 UK 113
7.2.5 France 113
7.2.6 Germany 114
7.2.7 Italy 114
7.2.8 Spain 115
7.2.9 Japan 115
7.3 Abbreviations 116
7.4 References 117
7.5 Methodology 122
7.6 Secondary Research 122
7.7 Contact Us 122
7.8 Disclaimer 122
List Of Figure:
Table 1: Pancreatic Cancer Therapeutics, Inherited Cancer Syndromes Associated with an
Increased Risk of Pancreatic Cancer 11
Table 2: Pancreatic Cancer Therapeutics, Common Mutations in Pancreatic Cancer 12
Table 3: Pancreatic Cancer Therapeutics, Tumor Staging in Pancreatic Cancer 14
Table 4: Pancreatic Cancer Therapeutics, ECOG Performance Status Scores and Description 15

About Us
Radiant Insights is a platform for companies looking to meet their market research and business
intelligence requirements. We assist and facilitate organizations and individuals procure market
research reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro markets. In addition to
over extensive database of reports, our experienced research coordinators also offer a host of
Ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Website: Radiant Insights
Visit Our Blog: radiantri.blogspot.com